Accustem Sciences Inc. financial data

Symbol
ACUT on OTC
Industry
Pharmaceutical Preparations
Location
5 Penn Plaza, 19 Th Floor, #1954, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Former names
AccuStem Sciences Ltd (to 7/1/2021)
Latest financial report
10-K - Q4 2024 - Apr 3, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.74 % -81.3%
Debt-to-equity -103 % +12.5%
Return On Equity 50.1 % -61.8%
Return On Assets -1.74K % -133%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 12.1M shares +6.65%
Common Stock, Shares, Outstanding 12.1M shares +6.65%
Entity Public Float 2.18M USD -86.4%
Common Stock, Value, Issued 12.1K USD +6.65%
Weighted Average Number of Shares Outstanding, Basic 11.4M shares +0.78%
Weighted Average Number of Shares Outstanding, Diluted 11.4M shares +0.78%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 138K USD -0.96%
General and Administrative Expense 1.37M USD -28.5%
Operating Income (Loss) -1.51M USD +26.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.51M USD +26.6%
Net Income (Loss) Attributable to Parent -1.51M USD +26.6%
Earnings Per Share, Basic -0.13 USD/shares +27.8%
Earnings Per Share, Diluted -0.13 USD/shares +27.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 50.4K USD -61.2%
Property, Plant and Equipment, Net 418 USD -89.7%
Assets 50.9K USD -62%
Accounts Payable, Current 805K USD +39.1%
Accrued Liabilities, Current 164K USD +4.87%
Liabilities, Current 3.36M USD +49.8%
Liabilities 3.36M USD +49.8%
Retained Earnings (Accumulated Deficit) -8.03M USD -23.1%
Stockholders' Equity Attributable to Parent -3.31M USD -56.9%
Liabilities and Equity 50.9K USD -62%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -237K USD +46.8%
Net Cash Provided by (Used in) Financing Activities 225K USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 12.1M shares +6.65%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -12.1K USD +97.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 697 USD -0.71%
Deferred Tax Assets, Valuation Allowance 1.74M USD +28%
Depreciation 3.63K USD 0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -3.79M USD -157%
Property, Plant and Equipment, Gross 11K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 1.59M USD +29.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 4.7M USD +6.88%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.74M USD +28%
Share-based Payment Arrangement, Expense 169K USD +497%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%